TPWA
DRUG

Twin Peaks Wealth Advisors’s Bright Minds Biosciences DRUG Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$73 – 761
2026
Q1 		$73 Buy
+1
New +$80 ﹤0.01% 2272

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Twin Peaks Wealth Advisors's DRUG Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Bright Minds Biosciences (DRUG) in Q2 2026, closing a stake of 1 share — an estimated $73 sold.

Twin Peaks Wealth Advisors first reported a position in DRUG in Q1 2026 and held it in 1 quarter. The position peaked at $73 in Q1 2026. 100 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining Bright Minds Biosciences position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 1 Bright Minds Biosciences share in Q2 2026, an estimated $73.
  • Twin Peaks Wealth Advisors first reported a position in Bright Minds Biosciences in Q1 2026 and held it in 1 quarter.
  • Twin Peaks Wealth Advisors's Bright Minds Biosciences position peaked at $73 in Q1 2026.
  • 100 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.